Participants in the study will take the medication in the form of a capsule, which is taken by mouth once a day. The study will monitor the response to the treatment over a period of time to see how well it works in managing the conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to gather information on how the medication affects the body and its potential side effects.

By participating in this study, researchers hope to better understand the effectiveness of gandotinib in treating myeloproliferative neoplasms and to explore its potential as a treatment option for patients with these conditions. The study will help determine if this medication can improve the quality of life for those affected by these blood cancers.

The treatment being tested is iadademstat, which will be taken as an oral solution, meaning a liquid medicine swallowed by mouth. The main goal of the study is to see if this new medicine can help reduce platelet counts to a normal range and to monitor any side effects that may occur during the process.

The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.

Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.

The purpose of the study is to evaluate how safe and effective Ruxolitinib is compared to other treatments for patients with high-risk forms of these blood disorders. Participants in the study will receive either Ruxolitinib or the best available therapy, which may include other medications or treatments that are commonly used for these conditions. The study will last for a period of up to 145 days, during which participants will be monitored to assess their response to the treatment and any side effects they may experience.

Throughout the study, researchers will look at various outcomes, such as the rate of complete responses in blood cell counts and the reduction of symptoms related to the disorders. The study aims to provide valuable information on the potential benefits and risks of using Ruxolitinib for treating high-risk Polycythemia Vera and Essential Thrombocythemia, helping to improve future treatment options for these conditions.

The purpose of the study is to compare the effectiveness of Bomedemstat to Hydroxycarbamide in managing Essential Thrombocythemia. Participants in the study will be randomly assigned to receive either Bomedemstat, Hydroxycarbamide, or a placebo. The study will last for a period of up to 36 months, during which participants will take the medication orally in the form of capsules. Throughout the study, participants will be monitored regularly to assess their response to the treatment and to check for any side effects.

This trial aims to provide valuable information on which treatment might be more beneficial for managing Essential Thrombocythemia. By participating, individuals contribute to research that could improve future treatment options for this condition. The study is designed to ensure the safety and well-being of all participants, with regular check-ups and assessments conducted by healthcare professionals.

The purpose of the study is to compare the effectiveness and safety of Bomedemstat against other treatments that are currently available. Participants in the study will receive either Bomedemstat or another treatment, which could include medications like Ruxolitinib, Peginterferon Alfa-2a, Anagrelide Hydrochloride Monohydrate, or Busulfan. Some participants may receive a placebo. The study will last for a period of up to 36 months, during which time participants will be monitored for their response to the treatment and any side effects they may experience.

Throughout the study, researchers will assess various outcomes, such as the rate of durable clinicohematologic response, which refers to how well the blood disorder is controlled over time. They will also look at changes in symptoms and overall health, as well as any adverse events or complications that may occur. The goal is to determine if Bomedemstat is a safe and effective option for managing Essential Thrombocythemia in patients who have limited treatment options.

The purpose of the study is to evaluate the safety and tolerability of bomedemstat. Participants in this study have previously been involved in a bomedemstat clinical trial and have been receiving the medication for at least six months. The study will continue to monitor these participants to ensure the treatment remains safe and to observe any potential side effects. Participants will take the medication at home and will be required to swallow the capsules as directed.

Throughout the study, researchers will keep track of any adverse events, which are unwanted effects that may occur during treatment. They will also monitor whether participants need to stop the treatment due to these effects. For those with essential thrombocythemia or polycythemia vera, the study will look at how long the treatment continues to work effectively. Additionally, the study will observe if there is any progression to more serious conditions like myelodysplastic syndrome or acute myeloid leukemia. The study aims to provide valuable information on the long-term use of bomedemstat for these conditions.

The purpose of the study is to see how well ropeginterferon alfa-2b works in managing Essential Thrombocythemia in patients who have limited options due to intolerance or lack of response to other treatments. Participants in the study will receive the medication over a period of time, and their response to the treatment will be monitored. The study will look at how the medication affects blood cell counts and whether it helps prevent complications like blood clots or bleeding. The study will also assess any changes in symptoms and overall health during the treatment period.

Throughout the study, participants will be regularly checked to ensure their safety and to monitor the effects of the treatment. The study aims to provide valuable information on the use of ropeginterferon alfa-2b for patients with Essential Thrombocythemia who have not had success with other treatments. This research could potentially offer a new option for managing this condition and improving the quality of life for those affected.